Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | ROS1 | P08922 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4614381 | 0.89 | HPGD (0.77) | HPGDLMNAL3MBTL1MAPTKMT2A | |
| SCHEMBL20372815 | 0.86 | HPGD (0.68) | HPGDLMNAL3MBTL1MAPTKMT2A | |
| SCHEMBL21755120 | 0.86 | HPGD (0.73) | HPGDLMNAL3MBTL1MAPTKMT2A | |
| SCHEMBL9202532 | 0.81 | HPGD (0.50) | HPGDLMNAL3MBTL1MAPTKMT2A | |
| SCHEMBL255294 | 0.80 | KEAP1 (0.54) | HPGDLMNAMAPTKMT2APTGS1 | |
| SCHEMBL20098247 | 0.79 | BRAF (0.56) | LMNAKMT2ANAMPTPTGS1KDM4E | |
| Hydrochloric Acid SCHEMBL31111910 | 0.78 | KEAP1 (0.52) | HPGDLMNAMAPTKMT2APTGS1 | |
| SCHEMBL10191923 | 0.78 | CA1 (0.53) | HPGDLMNAMAPTKMT2APTPN5 | |
| SCHEMBL7023386 | 0.78 | HPGD (0.55) | HPGDLMNAL3MBTL1MAPTKMT2A | |
| SCHEMBL526840 | 0.77 | BRAF (0.49) | HPGDLMNAL3MBTL1MAPTNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10398706-B2 | Heteroaryldiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180193352-A1 | HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| CN-100503677-C | Catalyst for selective isocyanate dimerization | BAYER MATERIALSCIENCE AG (DE) | 2009-06-24 | — | — | CN | disclosed |
| EP-1656405-B1 | NOVEL CATALYSTS FOR SELECTIVE ISOCYANATE DIMERISATION | BAYER MATERIALSCIENCE AG (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-7317112-B2 | Catalysts for selective isocyanate dimerization | BAYER MATERIALSCIENCE AG (DE) | 2008-01-08 | — | — | US | disclosed |
| CN-1832975-A | Novel catalysts for selective isocyanate dimerization | BAYER MATERIALSCIENCE AG (DE) | 2006-09-13 | — | — | CN | disclosed |
| EP-1656405-A1 | NOVEL CATALYSTS FOR SELECTIVE ISOCYANATE DIMERISATION | Bayer MaterialScience AG (DE) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005016984-A1 | NOVEL CATALYSTS FOR SELECTIVE ISOCYANATE DIMERISATION | BAYER MATERIALSCIENCE AG (DE) | 2005-02-24 | — | — | WO | disclosed |
| US-20050033006-A1 | Sulfonamide ions as catalysts for dimerization | BAYER MATERIALSCIENCE AG (DE) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398706-B2 | Heteroaryldiazepine derivatives as RSV inhibitors | CYP3A5, CYP3A43, CYP3A4 | HPGD 717/4885LMNA 2837/4885L3MBTL1 4672/4885 |
| US-20180193352-A1 | HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | CYP3A5, CYP3A43, CYP3A4 | HPGD 717/4885LMNA 2837/4885L3MBTL1 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.